Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease that results from a break in immune tolerance to self-antigens, leading to multi-organ destruction. Autoantibody deposition and inflammatory cell infiltration in target organs such as kidneys and brain lead to complications of this disease. Dysregulation of cellular and humoral immune response elements, along with organ-defined molecular aberrations, form the basis of SLE pathogenesis.

Aberrant T lymphocyte activation due to signaling abnormalities, linked to defective gene transcription and altered cytokine production, are important contributors to SLE pathophysiology. A better understanding of signaling and gene regulation defects in SLE T cells will lead to the identification of specific novel molecular targets and predictive biomarkers for therapy.

**Introduction**

Systemic lupus erythematosus (SLE) is a chronic debilitating autoimmune disease of unknown etiology that mainly affects women in the childbearing years (1, 2). The disease follows an unpredictable course of flares and remission with no predictive biomarkers for either phase. Current steroid-based immunosuppressive therapies are not specific and have undesirable adverse effects, rendering patients immunocompromised and susceptible to infections. SLE pathophysiology involves abnormal immune cell activation, leading to autoantibody and immune complex deposition in target organs such as the skin, joints, kidneys, and brain with potentially fatal complications.

There is increasing interest in the role of T cells in the pathophysiology of the disease, as they display an interesting phenotype. T cells have the ability to provide excessive help to B cells, but fail to raise proper cytotoxic responses to fend off infections. At the cytokine level, they fail to produce sufficient amounts of IL-2, although they produce increased amounts of IL-17 and IL-10. An understanding of the molecular events that occur inside the SLE T cells following antigen (autoantigen) engagement has been considered mandatory to resolving their aberrant function. It is also expected that correction of abnormal signaling molecules should correct T cell function and limit subsequent pathology that leads to clinical manifestations.

In this Review, cell signaling and gene regulation abnormalities in T cells from patients with SLE and lupus-prone mice will be presented with emphasis on how they contribute to aberrant T cell function and how they can be explored as therapeutic targets.

**Altered response to antigen/autoantigen**

T cells recognize antigen through the TCR in conjunction with the CD3-defined complex of transmembrane proteins (ε, δ, γ, and ζ) to instigate a signaling process, which, along with input from coreceptors and receptors for cytokines, dictates effector cell function. In SLE T cells, the TCR/CD3 complex is “rewired” whereby the CD3ζ chain is reduced and replaced by the homologous Fc receptor common γ subunit (FcyR) chain (ref. 3 and Figure 1). Unlike CD3ζ, which recruits ζ-associated protein kinase 70 kDa (ZAP70) to relay the signal, FcRγ recruits the spleen tyrosine kinase (Syk). Because FcRγ/Syk transfers a manyfold stronger signal than CD3ζ/ZAP70, the SLE T cell exhibits early and heightenened signaling events and probably responds sufficiently when it meets low-avidity autoantigens to which a normal T cell would not respond. Pharmacologic inhibition of Syk in lupus-prone MRL/lpr mice results in significant reduction of autoimmunity and organ (kidney and skin) pathology even if treatment is initiated after the onset of the disease. Silencing or pharmacologic inhibition of Syk in T cells from patients with SLE corrects aberrant signaling (4), and replacement of CD3ζ normalizes IL-2 production (5).

Exploration of mechanisms that account for the decreased expression of CD3ζ in SLE T cells has proved informative, because several pathways can be targeted to increase CD3ζ levels and correct T cell function. For example, transcription (6), mRNA stability (7), alternative splicing (8), proteasome degradation (9), caspase cleavage (10), and mTOR-dependent degradation (11) can all be targeted to treat SLE through the correction of excessive early signaling events. The decrease in CD3ζ is obviously a downstream event, but it cannot be ignored because it may contribute to the ability of T cells to home to tissues inappropriately and cause inflammation. This is inferred by observations in CD3ζ-deficient mice in which T cells accumulate in multiple organs, particularly when challenged with alloantigens or polyinosinic:polycytidylic acid (poly I:C) (12).

T cell activation, differentiation, function, and death are regulated by reactive oxygen intermediates (ROIs) and ATP synthesis. Mitochondrial transmembrane potential is a critical regulator of ROI and ATP generation. Aberrant, persistent mitochondrial hyperpolarization, increased ROI production (or reduced glutathione levels), and ATP depletion in SLE T cells mediate spontaneous apoptosis and decreased activation-induced apoptosis. In addition,
oxidative modifications of self-antigens can trigger autoimmunity. Correlations between these modified serum proteins and disease activity and organ damage have been observed in SLE (13). The serine/threonine kinase mTOR is a sensor of mitochondrial membrane potential that activates numerous downstream substrates and is aberrantly increased in T cells from patients with SLE (11). Therapeutic targeting of mTOR with rapamycin in SLE patients leads to normalized T cell activation, calcium fluxing, and clinical improvement (14). Inhibition of mTOR with epigallocatechin-3-gallate (EGCG) attenuates inflammation in mesangial cells from lupus-prone MRL/lpr mice (15). Importantly, N-acetylcysteine reduced disease activity in SLE patients in a pilot double-blind, placebo-controlled trial (16), emphasizing that the study of T cell biochemistry substantially benefits the treatment of SLE patients.

Lipid rafts are sphingolipid/cholesterol/GM1-rich regions within the cell membrane that are scattered throughout the cell surface and contain the TCR/CD3 complex and associated signaling molecules. Whereas lipid rafts are uniformly distributed across the cell membrane of T cells from healthy individuals, these rafts appear to be preclustered and aggregated in SLE T cells, implying that SLE T cells are in an activated state (17). Dissolution of aggregated lipid rafts in SLE T cells ex vivo corrects TCR/CD3-mediated signaling (18, 19), and it has been proposed that statins, which inhibit 3-hydroxy-3-methylgluteryl CoA reductase, may dissolve lipid rafts and could potentially be repurposed to treat SLE, as would drugs that inhibit glycosphingolipid metabolism (20). It is premature to link the dyslipidemia that SLE patients frequently experience (21) to the formation of aggregated lipid rafts on the surface of T cells. In support of these propositions, dissolution of lipid rafts delays disease onset in MRL/lpr mice, while acceleration of lipid raft formation accelerates disease manifestation (22).

**Inappropriate lymphocyte homing to tissues**

T cells are present in inflamed tissues including the kidneys and the skin in SLE patients, aided by their increased ability to adhere to tissue elements. Their presence in the tubulo-interstitial space in the kidney tissue of patients with lupus nephritis has been linked to decreased preservation of renal function (1), and therefore T cells contribute to the inflammatory process in the tissue damage. As we discuss below (23), T cells produce IL-17, among other cytokines. T cells from lupus patients express increased amounts of CD44 (24), as do T cells from CD3ζ-deficient mice (12). CD44+ T cells, specifically those expressing the v3 and v6 isoforms, are present in the kidneys of patients with lupus nephritis (25). CD44 binds better to its ligand hyaluronic acid if linked to the phosphorylated form of ezrin/radixin/moeisin (ERM), which is phosphorylated by the Rho-associated protein kinase (ROCK) in both humans (26) and mice (27). Pharmacologic inhibition of ROCK in MRL/lpr mice has been clearly shown to limit both autoimmunity and renal disease (27), and therefore, ROCK inhibitors should be investigated in clinical trials.

**Excessive help to B cells**

It has been long established that T cells provide help to B cells to produce anti-dsDNA antibodies. Both CD4+ and CD3ζCD4 CD8 (double-negative) T cells, which are expanded in SLE patients (28), can help B cells, and this has provided the rationale to treat SLE patients with biologics designed to disrupt this interaction. The CD40 ligand/CD40 (CD40L/CD40) duo is among the dominant co-stimulatory pairs of molecules, and CD40L is increased on the surface of SLE T cells (29, 30). The increased expression of CD40L on the cell membrane of T cells is enabled by increased transcription of CD40L, which is caused by hypomethylation of the CD40L gene and increased binding of nuclear factor of activated T cells.
Interestingly, the levels and activity of PI3K \(\gamma\) cannot decrease in glomerulonephritis and prolonged survival (41).

Macrophage inhibition of PI3K regulates induction-induced T cell death, which is a known mechanism for the persistence of autoreactive cells (42). GS9029, a highly potent and selective pharmacologic inhibitor of PI3K\(\delta\), was used to treat MRL/\(lpr\) mice, resulting in limited macrophage infiltration into kidneys, significantly reduced pathology, and prolonged survival in mice, even when treatment was initiated after disease onset (43). PI3K\(\delta\) inhibitors are currently being tested in clinical trials for hematologic malignancies, which will generate sufficient information on its potential side effects prior to trials in SLE patients. Finally, T cell-specific AKT transgenic mice exhibit early mortality, high levels of autoantibodies and glomerulonephritis, and central and peripheral resistance to apoptosis similar to Bcl-xL T cell transgenic mice (44, 45), suggesting that AKT is a therapeutic target. In sum, it appears the PI3K/AKT pathway participates in the aberrant function of the SLE T cell and offers a number of potential therapeutic targets.

**Limited production of IL-2**

IL-2 is an important cytokine responsible not only for normal T cell activation and proliferation but also for activation-induced cell death, which is required for the deletion of autoreactive cells. Additionally, IL-2 is critical for cell-mediated immunity against infectious agents; infections account for the majority of deaths among SLE patients. Finally, Tregs depend on IL-2 for their survival and maintenance (46). IL2 mRNA is decreased in T cells from SLE patients and several lupus-prone mouse strains (47). Since its stability is normal, the levels of IL-2 are determined at the level of transcription (47).

IL2 transcription is complex, and the IL2 promoter region includes binding elements for a large number of transcription factors including NF-\(\kappa\)B, NFAT, activator protein 1 (AP1), OCT1, cAMP response element binding protein (CREB), and cAMP response element modulator (CREM). Both NF-\(\kappa\)B and AP1 are decreased in SLE T cells and contribute to decreased IL2 transcription (48, 49). It appears that an imbalance between the transcription factors CREB and CREM is also important in determining the rate of IL2 transcription. Both transcription factors recognize (NFAT) to its promoter (31, 32). NFAT is activated by the tyrosine phosphatase calcineurin, the activity of which is facilitated by increased intracytoplasmic calcium levels following engagement of the TCR/CD3 complex. Interestingly, cyclosporin, which inhibits calcineurin, has not been a focus in SLE treatment because of its nephrotoxicity. However, dipyridamole, a drug that prevents calcineurin-mediated dephosphorylation of NFAT, limits the expression of CD40L in T cells from patients with SLE and lupus-prone mice, prevents kidney and skin pathology (33), and can be repositioned as an adjuvant in the treatment of SLE. Thus, dipyridamole appears to perform an “inside” job in reducing CD40L, obviating the use of CD40L-blocking biologics, which have been linked to thrombotic events when used in patients with SLE (34).

Inducible T cell co-stimulator (ICOS) is another molecule that provides co-stimulatory signals upon interaction with its ligand ICOSL and is an essential co-stimulatory receptor for follicular T helper cells (Tfh) cells. Using lupus-prone, ICOS-deficient mice (35) or mice overexpressing ICOS (36), it has been shown that ICOS is necessary for extrafollicular B cell differentiation, IL-21 production, and CD4 helper function. Increased numbers of circulating Tfh cells have been reported in patients with active SLE (37). The ICOS signaling pathway requires the PI3K p110\(\delta\), and Tfh cell development requires the presence of p110\(\delta\).

Transgenic overexpression of PI3K or expression of an activity-increasing p85 mutant leads to an autoimmune phenotype in mice (38). Deletion of PI3K\(\delta\) impairs antigen receptor signaling in both T cells and B cells (39), and PI3K\(\delta\) deficiency impairs T cell activation and migration of macrophages and neutrophils (40). Deletion of PI3K\(\gamma\) in lupus-prone mice ameliorates disease (40), and pharmacologic inhibition of PI3K\(\gamma\) with AS605240 leads to a significant decrease in glomerulonephritis and prolonged survival (41). Interestingly, the levels and activity of PI3K\(\delta\) were increased in PBMCs from patients with SLE and conferred resistance to activation-induced T cell death, which is a known mechanism for the persistence of autoreactive cells (42). GS9029, a highly potent and selective pharmacologic inhibitor of PI3K\(\delta\), was used to treat MRL/\(lpr\) mice, resulting in limited macrophage infiltration into kidneys, significantly reduced pathology, and prolonged survival in mice, even when treatment was initiated after disease onset (43). PI3K\(\delta\) inhibitors are currently being tested in clinical trials for hematologic malignancies, which will generate sufficient information on its potential side effects prior to trials in SLE patients. Finally, T cell-specific AKT transgenic mice exhibit early mortality, high levels of autoantibodies and glomerulonephritis, and central and peripheral resistance to apoptosis similar to Bcl-xL T cell transgenic mice (44, 45), suggesting that AKT is a therapeutic target. In sum, it appears the PI3K/AKT pathway participates in the aberrant function of the SLE T cell and offers a number of potential therapeutic targets.

**Limited production of IL-2**

IL-2 is an important cytokine responsible not only for normal T cell activation and proliferation but also for activation-induced cell death, which is required for the deletion of autoreactive cells. Additionally, IL-2 is critical for cell-mediated immunity against infectious agents; infections account for the majority of deaths among SLE patients. Finally, Tregs depend on IL-2 for their survival and maintenance (46). IL2 mRNA is decreased in T cells from SLE patients and several lupus-prone mouse strains (47). Since its stability is normal, the levels of IL-2 are determined at the level of transcription (47).

IL2 transcription is complex, and the IL2 promoter region includes binding elements for a large number of transcription factors including NF-\(\kappa\)B, NFAT, activator protein 1 (AP1), OCT1, cAMP response element binding protein (CREB), and cAMP response element modulator (CREM). Both NF-\(\kappa\)B and AP1 are decreased in SLE T cells and contribute to decreased IL2 transcription (48, 49). It appears that an imbalance between the transcription factors CREB and CREM is also important in determining the rate of IL2 transcription. Both transcription factors recognize...
a CRE site at the –180 bp position within the core IL2 promoter. Phosphorylation leads to the activation of these proteins, and the relative amounts of p-CREB versus p-CREM determine binding to the promoter and the consequent activation or suppression of IL-2 expression, as p-CREB activates while p-CREM represses IL2 transcription. In SLE T cells, decreased PKA activity leads to dephosphorylation of CREB (50) and shifts the balance toward increased p-CREM levels. More importantly, increased levels and activity of the serine threonine protein phosphatase 2A (PP2A) account for the dephosphorylation of p-CREB (Figure 2), which allows the repressor CREM to bind to the –180 bp site of the promoter. In addition, calcium calmodulin kinase IV (CAMKIV), which is increased in the nuclei of SLE T cells, phosphorylates CREM to increase p-CREM levels and therefore suppresses IL2 transcription (51). More recently it was shown that binding of CREM occurs in a number of sites across the IL2 locus, where it recruits histone deacetylase 1 (HDAC1), DNA methyltransferase 1 (DNMT1), and G9α, which act together to close the locus and limit the production of IL2 mRNA (52). Recent work has suggested the role of serine/arginine-rich splicing factor 1 (SRSF1), a splicing regulator whose expression was reduced in T cells from several patients with SLE, more so in patients with worse disease. Importantly, forced expression of SRSF1 into SLE T cells rescues IL-2 production through a transcription-related mechanism (53).

**Increased production of IL-17**

Recently IL-17 has received much attention as an important contributor to inflammation and autoimmunity (54). Increased amounts of IL-17 cytokine as well as an increased proportion of IL-17-producing CD4+ T cells have been observed in the serum and peripheral blood of SLE patients (55). Increased numbers of IL-17-producing, double-negative T cells circulate in the peripheral blood of patients with SLE and in the kidneys of patients with lupus nephritis (23).

Under appropriate priming conditions, especially in the presence of inflammatory signals such as IL-6, IL-23, IL-21, and TGF-β, CD4 T cells undergo specific differentiation to become IL-17 producers, also known as Th17 cells (56, 57). Transcriptional activation of **IL17** is mediated by the retinoid-related orphan receptor γt (RORγt) and RORα proteins, of which RORγt is essential for IL-17 production and is expressed only in Th17-differentiated cells (58). While IL-21 is important for the induction of IL-17, maintenance of IL-17 production requires IL-23. Genetic deficiency of the IL-23 receptor in lupus-prone C57BL/6/lpr mice leads to reduced frequency of double-negative T cells, reduced IL-17 production, and amelioration of kidney disease (59). IL-17–deficient mice were protected from the development of pristane-induced lupus, autoantibody production, and glomerulonephritis (60). IL-6, IL-21, and IL-23 activate STAT3, which can directly bind and activate **IL17** and **IL21** (61). STAT3 expression in SLE T cells is high and contributes to the increased chemokine-directed migratory capacity of these inflammatory cells (62). Besides its proinflammatory role, IL-17 also activates anti-dsDNA antibody production, as evidenced by high antibody production in PBMCs from patients with lupus nephritis (63). Lastly, epigenetic modifications invoked by STAT3 appear to account for the increased production of IL-10 in patients with SLE (64, 65).

Mice overexpressing CREMα in T cells predictably produce less IL-2 (66) and interestingly produce more IL-17. CREMα was found to bind to the **IL17** promoter and to enhance its activity in vitro. In addition to the promoter, CREMα binds to additional sites across the **IL17** locus but, unlike the **IL2** locus, keeps the **IL17** locus open because it fails to recruit HDAC1, G9α, and DNMT1 (67). Thus it appears that a single transcription factor, CREMα, accounts for both increased IL-17 production and decreased IL-2 production (Figure 3). Furthermore, the production of CREMα is determined at the transcriptional level, mainly through the increased binding of the transcription factor SPI1. The production of SPI1 seems to be influenced by hormones such as estrogen (68), which provides a molecular link to the preponderance of female SLE patients. We should note that SPI1 is activated after it becomes dephosphorylated by PP2A (69). IL-17 production is further controlled by interferon regulatory factor 4 (IRF4), which is phosphorylated by ROCK2, a protein that is increased in lupus-prone mice (27).

Collectively, IL-17 production in SLE patients and lupus-prone mice is controlled by a number of transcription factors, epigenetic changes, and input from additional cytokines such as IL-23. This information and the fact that anti-IL-17 antibodies are useful in the treatment of psoriasis, psoriatic and rheumatoid arthritis, and uveitis (70, 71) strongly suggest that blockade of the IL-23/IL-17 axis should be evaluated in the treatment of SLE.

**Aberrant distribution of T cell subsets**

**CD3+CD4–CD8+ double-negative T cells**. As mentioned above, double-negative T cells are expanded in SLE patients and in lupus-prone mice. Because they share a number of genes with CD8+ T cells, it has been proposed that at least a percentage of them must derive from activated CD8+ T cells in the periphery (72). Loss of CD8 in activated T cells in both SLE patients and MRL/lpr mice appears to be caused by CREMα, which binds to the CD8 locus, recruits HDAC1, G9α, and
DNMT1, and closes the chromatin (73). Because the expression of CREMα is regulated by S6 kinase, a canonical substrate of mTORC1 (74), it is possible that the expression of CD8 is also regulated through this pathway. In addition, there is evidence that mTORC1 is prominently activated in double-negative T cells (16) and, when blocked, limits their numbers in patients with SLE (75).

**Effectors T cells.** Effector CD4+ T cells are expanded in SLE patients and produce less IL-2 and more IL-17 than CD4+ T cells in healthy controls (67). It has been shown that CREMα limits the production of IL-2 and enhances the production of IL-17 in order to expand effector T cells in SLE patients (67). Thus, CREMα alone explains the aberrant numbers of potentially pathogenic T cell subsets.

**Invariant NK T cells.** NK T cells are a unique T cell lineage, and those bearing an invariant TCR recognize certain glycolipid antigens in the context of CD1-d (non-classical MHC) molecules (76). Invariant NK T cells play an immunoregulatory role through their cytokine production and cytotoxicity and are implicated in the development of autoimmune disease. Reduced numbers of NKT cells are observed in the peripheral blood of patients with SLE, and NKT cell deficiency is inversely correlated with disease activity. In addition, proliferation and cytokine production are impaired (77–79).

**Compromised Treg function.**
Tregs are responsible for the control of the immune response in the periphery, and defective function or decreased numbers contribute to the pathogenesis of several autoimmune diseases including type 1 diabetes and multiple sclerosis. The number and/or function of Tregs in the peripheral blood of patients with SLE are reportedly decreased and therefore have been considered culprits in the peripheral control of the autoimmune effector response (80). Decreased production of IL-2 has been linked to the poor numbers and function of Tregs in SLE patients. The ability of low doses of IL-2 to control hepatitis C–linked vasculitis (81) and graft-versus-host disease (82) by augmenting Treg numbers and function has indicated that therapeutic enhancement of Tregs could be used for the treatment of SLE.

We and others have been searching for abnormally expressed kinases and phosphatases in patients with SLE and lupus-prone mice that would account for defective Treg function. CaMKIV is found at increased levels in the nuclei of SLE T cells following engagement of the CD3/TCR complex (83). CaMKIV expression is increased in T cells from lupus-prone MRL/lpr mice, and its inhibition with the small drug KN-93 leads to the suppression of nephritis and skin disease (51). Genetic deletion improved survival, restored IL-2 production, curbed excessive T cell activation, and increased Treg numbers and function. Silencing CaMKIV in SLE T cells increased the expression of FOXP3 upon activation and induction with TGF-β (84). Furthermore, genetic deficiency of CaMKIV or inhibition with KN-93 decreased the frequency of IL-17–producing CD4 and double-negative T cells and ameliorated EAE and lupus-like disease in mice. At the biochemical level CaMKIV was found to act through the AKT/mTOR and CREMα pathways (85).

mTOR is present in two different complexes, mTORC1 and mTORC2, which have distinct components and downstream functions (86). mTORC1 is important for Th1 and Th17 differentiation, and mTORC2 is essential for Th2 differentiation in mice. Both complexes suppress FOXP3 expression and thereby inhibit Treg differentiation. Accordingly, inhibition of mTOR with rapamycin enhances Treg generation in vitro and in vivo (87–89). Recent work has demonstrated that compared with healthy controls, T cells from patients with SLE exhibited increased mTORC1 activity (mainly in double-negative T cells) and reduced mTORC2 activity. mTORC1 promoted a Th17 phenotype in CD4+ T cells, IL-4 production in double-negative T cells, and a reduction in Tregs (87). In a prospective clinical trial, mTORC1 blockade with rapamycin reversed the expansion of double-negative T cells, reduced IL-4 production, and significantly improved disease in patients with SLE (75). In this longitudinal study, the expansion of double-negative cells correlated with disease activity and mTORC1 activation preceded disease flares by approximately four months. These results suggest that mTOR is a driver and predictor of disease and a potential biomarker and therapeutic target for SLE.
Treg cells do not proliferate in vitro and in this state are considered anergic. Anergic Tregs display active mTOR, and blockade with rapamycin makes them proliferate and amplifies their function (90). Leptin, a molecule known to be linked to autoimmunity (91), promotes mTOR activity (92). This observation, along with the fact that leptin promotes IL-17 production by inducing RORγt expression (93), makes leptin a treatment target in lupus.

Epigenetic control of molecules important in SLE

Epigenetic events are important in activation, differentiation, and function of T cells, and dysregulation of these events can lead to altered gene expression, function, and autoimmune response (94, 95). Epigenetic changes can activate or suppress gene expression by regulating chromatin conformation and the accessibility of DNA to transcription factors and RNA polymerase. DNA CpG methylation and histone modifications are the most well-known epigenetic mechanisms (64). Hypermethylation of DNA suppresses gene expression via inactivation of chromatin, while hypomethylation of DNA leads to chromatin activation and increased gene expression. Patients treated with procainamide or hydralazine, which decrease DNA methylation, developed lupus-like disease, providing direct evidence for the role of epigenetics in the pathogenesis of autoimmunity. SLE is characterized by hypomethylation of numerous genes, including CD11a, perforin, CD70, and CD40L, resulting in their consequent aberrant expression and contribution to disease pathophysiology (96). A number of cytokine genes are overexpressed in CD4+ T cells in a chromatin-dependent manner including IL4, IL10, IL13, and IL17 (64). Recently it has been shown that the IL10 gene is hypomethylated in SLE T cells and allows for chromatin remodeling and p-STAT3 recruitment to its promoter to increase IL-10 expression (65). The promoter of the serine/threonine phosphatase PP2A is hypomethylated, resulting in its overexpression and aberrant activity in T cells from SLE patients (97). The expression and activity of DNMT1, which is responsible for DNA methylation, were reduced in SLE T cells, accounting for the observed global hypomethylation (98). PP2A, which is overexpressed in SLE T cells, decreases the activity of DNMT1 through dephosphorylation of ERK and MEK and consequently increases expression of the methylation-sensitive genes CD70 and CD11a (99). Growth arrest and DNA damage–induced 45a (GADD45a) induces DNA hypomethylation in CD4+ T cells in SLE patients and contributes to lupus-like autoimmunity (100). As discussed above, CREMα causes epigenetic alterations of the IL2, IL17, and IL10 loci. Study of the epigenetic control of gene expression in SLE will eventually explain how epigenetic alterations mediate SLE pathogenesis, which is not explained by genetics.

Conclusions

The development of novel, disease-specific, and side effect-free drugs for SLE has met unprecedented obstacles for a number of reasons. The T cell in patients with SLE presents a fascinating phenotype, which is now better understood after gaining insight into the underlying cell signaling and gene regulation. The preclustering of lipid rafts with altered composition explained why T cells are overreactive, whereas the increased expression of CaMKIV in the nucleus explained the increased binding of CREMs to the IL2 and IL17 loci, which confers specific epigenetic changes that lead to decreased IL-2 and increased IL-17 production. Increased expression of PP2A contributes to the dephosphorylation of a number of molecules including Elf-1, SPI, MEK, and CREB and thus serves as a central node in aberrant T cell function. The concept that the two dozen or so regulatory subunits of the PP2A holoenzyme may regulate specific cell functions offers additional options for therapeutic targeting. As outlined in this Review, the ongoing efforts to understand what goes on inside the T cell have identified a number of viable therapeutic targets (Table 1) that could potentially be manipulated with small-molecule–based drugs. The use of small molecules should supersede that of biologics, as the clinical utility can be maximized by titrating dosages. Eventually, small-molecule drugs and/or gene targeting to correct the expression of molecules only in patients in whom they are abnormally expressed should be expected to meet success. Along these lines a gene expression array has been developed (101, 102) to determine the aberrant expression of signaling molecules in patients with SLE, pointing to the possibility that patients with SLE can be stratified along their molecular profiles.

Acknowledgments

The authors acknowledge funding support from NIH grants K01AR060781, R01AI42269, R37AI49954, R01AI068787, R01AI085567, and R01AR064350.

Address correspondence to: Vaishali R. Moulton or George C. Tsokos, 5 Blackfan Circle, CLS-928, Boston, Massachusetts 02115, USA. Phone: 617.735.4161; E-mail: vmoulton@bidmc.harvard.edu (V.R. Moulton), gtsokos@bidmc.harvard.edu (G.C. Tsokos).


49. Kyttarits VC, Zhang Z, Kuchroo VK, Ouuka M, Tsokos GC. Cutting edge: IL-23 receptor...


